CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.
For Fiscal Year Ending Dec 31, 2022
Sign up today and receive company updates straight to your inbox.
CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. In November 2022, CohBar announced that it had initiated a process to explore and review a range of strategic alternatives.
CohBar, Inc.
1455 Adams Drive
Suite 1308
Menlo Park, CA 94025
T: (650) 446-7888
info@cohbar.com
T: (650) 446-7888
TSX Trust Company
301 – 100 Adelaide St W
Toronto, ON M5H 4H1